Quick search:
Content Ideas
| Result | Content Idea | Research |
|---|---|---|
| Result | Content Idea | Research |
| 1 | Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review |
|
| 2 | Genmab and Seagen's BLA for tisotumab vedotin accepted for priority re |
|
| 3 | BLA Submitted for F-627 to Treat Chemo-Induced Neutropenia in Breast Cancer |
|
| 4 | Provention Bio gives update on teplizumab BLA, FDA feedback |
|
| 5 | BLA! to Represent Mr. Men and Little Miss in EMEA |
|
| 6 | Kite submits supplemental BLA for Tecartus to treat advanced ALL |
|
| 7 | Guess Who's Behind the New Menu at Downtown's Bar Leather Apron |
|
| 8 | FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review |
|
| 9 | Provention Bio shares struggle after FDA feedback on teplizumab BLA, analyst downgrades |
|
| 10 | VERIFY: What's the difference between Emergency Use Authorization and FDA approval? |
|
| 11 | TG Therapeutics completes rolling submission of ublituximab combo BLA as leukemia treatment |
|
| 12 | France Ridesharing Market 2021 Global Insights and Business Scenario- Bla bla Car, goCarShare, Zify France, Flix Mobility, Carpool World, Mobicoop – KSU | The Sentinel Newspaper |
|
| 13 | Molecular epidemiology of mcr-1, blaKPC-2, and blaNDM-1 | IDR |
|
| 14 | Rolling BLA for Ublituximab and Umbralisib in CLL Completed for FDA Submission |
|
| 15 | Philippines: Intellectual Property Office amends rules on mediation |
|
| 16 | Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer |
|
| 17 | Balochistan: BLA claims responsibility for bomb blast in Hub |
|
| 18 | CTD reveals SRA links with BLA |
|
| 19 | Balochistan CTD busts BLA cell, two killed |
|
| 20 | Ramadan arrangements reviewed at Bla |
|
| 21 | Not in the office? The best cafes and restaurants to work from in Dubai |
|
| 22 | Alexis Morante launches into fiction in El universo de Óliver |
|
| 23 | Exclusive: Actor-Comedian Chris Tucker gives advice to young black golfers in Augusta |
|
| 24 | 3 mega-venues opening in Dubai that you need on your radar |
|
| 25 | BLA claims Terror attack on Pakistan Army |
|
| 26 | DC Bla reviews implementation of PMAY Urban |
|
| 27 | TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting |
|
| 28 | MP Bla reviews implementation of CSSs, developmental projects |
|
| 29 | IBN ABDUR REHMAN (1930 — 2021) |
|
| 30 | There are 'definitely merits' to reparations, says the first Black Fed president |
|
| 31 | TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis |
|
| 32 | Journalist from Bla, bereaved |
|
| 33 | Transportation Aggregators Market In-depth Analysis, Competitive Landscape By 2026: Gett, Aritron, Beijing Xiaoju Keji Co., Ltd. (Didi Dache), Bla Bla Car, GrabTaxi Pte Ltd Block (Grab Taxi), Ola |
|
| 34 | Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
|
| 35 | 4 more trains to run between Bla-Budgam stations from April 1 |
|
| 36 | National [WATCH] COVID-19 briefing: Two deaths and 27 new cases |
|
| 37 | FDA Allows for Omalizumab Self-Injection Across All Indications |
|
| 38 | FDA could delay decision on AstraZeneca COVID-19 vaccine |
|
| 39 | Jacqueline Jossa and Dan Osborne hit out at online trolls for talking about their kids |
|
| 40 | Agriculture Dept organizes Farmers Workshop/ Seminar at Bla |
|
| 41 | Toronto Maple Leafs Trade Deadline Live Updates: At least one more deal likely to come from Kyle Dubas |
|
| 42 | Furious Dan Osborne threatens to ‘punch trolls heads in’ as Jacqueline Jossa claims abuse of kids is mak... |
|
| 43 | Transportation Aggregators Market Report 2021: COVID-19, Qualitative Analysis a |
|
| 44 | CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines |
|
| 45 | argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis |
|
| 46 | BrainStorm Receives Feedback on Potential BLA Submission for ALS Therapy |
|
| 47 | Janssen Files Rolling BLA Submission for on Cilta-Cel in R/R Multiple Myeloma |
|
| 48 | Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma |
|
| 49 | FDA Grants Priority Review to BLA for Retifanlimab as Possible Treatment for SCAC |
|
| 50 | Adcom gives thumbs up for islet therapy that may not have much market |
|
| 51 | Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review |
|
| 52 | Toripalimab Rolling Submission of BLA Initiated for Nasopharyngeal Carcinoma |
|
| 53 | FDA Accepts Bio-Thera’s BLA for Bevacizumab Biosimilar |
|
| 54 | Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug |
|
| 55 | Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer |
|
| 56 | FDA to Review BLA for Merck's Novel 15-Valent Pneumococcal Conjugate Vaccine |
|
| 57 | Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA |
|
| 58 | BLA Submission Delayed for Balstilimab For Treatment of Recurrent/metastatic Cervical Cancer |
|
| 59 | FDA Grants Priority Review to BLA for Vicineum for Treatment of High-Risk, BCG-Unresponsive NMIBC |
|
| 60 | Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals |
|
| 61 | Outlook Therapeutics' Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission |
|
| 62 | VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine |
|
| 63 | Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) |
|
| 64 | Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea |
|
| 65 | BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing… |
|
| 66 | FDA Accepts BLA for bluebird and BMS' Multiple Myeloma CAR-T Treatment |
|
| 67 | FDA Receives BLA for Lonca in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
| 68 | Janssen Submits BLA for Amivantamab to Treat Metastatic NSCLC with EGFR Exon 20 Insertion Mutations |
|
| 69 | FDA Accepts Biogen’s BLA for Alzheimer’s Candidate Aducanumab |
|
| 70 | FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review |
|
| 71 | What We're Reading: Public Transit Mask Mandate; BLA Decision on Alzheimer Drug Extended; Drug Pricing Rule Delayed |
|
| 72 | FDA Accepts BLA for Bevacizumab Biosimilar in Solid Tumors and Sets Action Date |
|
| 73 | Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy |
|
| 74 | Provention Bio Announces US FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals |
|
| 75 | Turning COVID-19 Vaccine EUA Into A BLA Will Require Six Months Of Additional Data |
|
| 76 | Manufacturers submit rolling BLA to FDA for CAR-T to treat advanced multiple myeloma |
|
| 77 | Immunocore to Submit BLA for Tebentafusp in Uveal Melanoma This Year |
|
| 78 | Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review |
|
| 79 | U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy |
|
| 80 | FDA Will Not Complete Review of BLA for Lisocabtagene Maraleucel By PDUFA Date |
|
| 81 | Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma |
|
| 82 | FDA Defers Action on BLA for Bevacizumab Biosimilar MYL-1402O |
|
| 83 | Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed |
|
| 84 | TG Therapeutics Initiates BLA for Ublituximab Combo to Treat CLL |
|
| 85 | FDA Issues CRL for Ropeginterferon alfa-2b-njft BLA in PV |
|
| 86 | Formycon confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* Biosimilar-Candidate FYB |
|
| 87 | Bla bla bla for biodiversity |
|
| 88 | Bluebird: delays push sickle cell therapy BLA back |
|
| 89 | Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD) |
|
| 90 | FDA Postpones Review of BLA for Liso-Cel in R/R Large B-Cell Lymphoma |
|
| 91 | Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag |
|
| 92 | BLA Submitted to FDA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer |
|
| 93 | DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years |
|
| 94 | Pogba pledges Man United loyalty after Raiola comments |
|
| 95 | Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review |
|
| 96 | BLA Initiated for JZP-458 in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma |
|
| 97 | Iovance plant on track for 2022 |
|
| 98 | FDA Defers BLA Action of Bevacizumab Biosimilar Due to COVID-19 Restrictions |
|
| 99 | CSLA Announces the 2021 Awards of Excellence Recipients |
|
| 100 | BioThera BLA for Roche Avastin biosimilar accepted by FDA |
|